AIM ImmunoTech

AIM

Market cap $10.7M

Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research

Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell unregistered Series I warrants (the “Series I Warrants”) to purchase up to 15,038,702 shares of Common Stock. The Series I Warrants will have an exercise price of $0.325 per share, will be exercisable subject to stockholder approval and will expire five (5) years from the initial exercise date.

SCHAUMBURG, Ill.--(BUSINESS WIRE)-- #isaca--CMMI Institute, a global leader in helping organizations reduce risk, boost performance, and build capability, is now extending this guidance to artificial intelligence, and has recently completed a pilot program for its new AI Maturity (AIM) framework. AIM enables organizations to assess, benchmark and improve how AI is implemented across real-world enterprise and regulatory environments, linking AI practices and governance to measurable, scalable outcomes. T.

Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, Fla.

Aimia Inc. (AIM:CA) Q1 2026 Earnings Call Transcript

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development of drugs for the treatment of cancer, today announced an agreement between the Company and certain accredited investors to exercise certain outstanding Class A, Class B, Class C, Class D, Class E and Class F Warrants (the “Existing Warrants”) to purchase up to an aggregate of 8,719,928 shares of common stock at a reduced exercise price of $0.48 per share for gross proceeds of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.

Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin